Novartis CEO Targets 20 Key Drugs as Potential Blockbusters - DCAT Value Chain Insights
Cause and Effect | SIX
It Paid Doctors Kickbacks. Now, Novartis Will Pay a $678 Million Settlement. - The New York Times
Novartis' Zykadia nears first-line lung cancer label - PMLiVE
NOVN: Novartis AG Stock Price Quote - SIX Swiss Ex - Bloomberg
Six Former and Current Novartis AG Execs Charged With Bribing Doctors in Korea | BioSpace
Novartis sells phase 3 rare disease drug to Pharming | Fierce Biotech
Novartis Annual Results | Novartis
NOVN: Novartis AG Stock Price Quote - SIX Swiss Ex - Bloomberg
Novartis is shutting down Colorado plant, laying off 400 employees after overestimating gene therapy demand | Fierce Pharma
A World of Opportunity
Novartis offre à Sandoz son autonomie et une cotation sur SIX | Radio Lac
Novartis - YouTube
Novartis to spin off generics business Sandoz next year | Reuters
AGC Biologics to buy Novartis facility in Longmont – Colorado Hometown Weekly
Novartis pays $100M for Mallinckrodt's priority review voucher
Investors | Novartis
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
NOVN Stock Price and Chart — SIX:NOVN — TradingView
